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Abstract
Background: E.coli type II L-asparaginase is widely used for treatment of acute lymphoblastic leukemia. However,
serious side effects such as allergic or hypersensitivity reactions are common for L-asparaginase treatment.
Methods for minimizing immune response on L-asparaginase treatment in human include bioengeneering of less
immunogenic version of the enzyme or utilizing the homologous enzymes of different origin. To rationalize these
approaches we compared immunogenicity of L-asparaginases from five bacterial organisms and performed
sequence-structure analysis of the presumable epitope regions.
Methods: IgG and IgM immune response in C57B16 mice after immunization with Wollinella succinogenes type II (WsA),
Yersinia pseudotuberculosis type II (YpA), Erwinia carotovora type II (EwA), and Rhodospirillum rubrum type I (RrA) and
Escherichia coli type II (EcA) L-asparaginases was evaluated using standard ELISA method. The comparative bioinformatics
analysis of structure and sequence of the bacterial L-asparaginases presumable epitope regions was performed.
Results: We showed different immunogenic properties of five studied L-asparaginases and confirmed the possibility of
replacement of EcA with L-asparaginase from different origin as a second-line treatment. Studied L-asparaginases might
be placed in the following order based on the immunogenicity level: YpA > RrA, WsA≥ EwA> EcA. Most significant cross-
immunogenicity was shown between EcA and YpA. We propose that a long N-terminus of YpA enzyme enriched with
charged aminoacids and tryptophan could be a reason of higher immunogenicity of YpA in comparison with other
considered enzymes. Although the recognized structural and sequence differences in putative epitope regions among
five considered L-asparaginases does not fully explain experimental observation of the immunogenicity of the enzymes,
the performed analysis set the foundation for further research in this direction.
Conclusions: The performed studies showed different immunogenic properties of L-asparaginases and confirmed the
possibility of replacement of EcA with L-asparaginase from different origin. The preferable enzymes for the second line
treatment are WsA, RrA, or EwA.
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Background
L-asparaginase (EC 3.5.1.1.) E. coli type II (EcA) has
been widely used for acute lymphoblastic leukemia treat-
ment for more than 30 years. The mechanism of antileu-
kemic activity is believed to be directly related to the
hydrolysis of L-asparagine and subsequent significant
depletion of L-asparagine concentration in blood and
death of cells that are not able to express asparagine
synthetase or have low level of expression [1]. It is
known that hypersensitivity, including several allergic re-
actions and even anaphylactic shock, are among the
most dangerous side effects of EcA treatment [2]. More-
over, even if a patient doesn’t have severe hypersensitivity
symptoms, the development of anti-EcA antibodies could
minimize the efficacy of treatment due to the alteration of* Correspondence: vadimpokrovsky@gmail.com
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pharmacokinetics and elimination the enzyme from the
blood.
A number of approaches to prevent the immunogenicity
of L-asparaginases has been investigated extensively:
chemical modifications of epitopes to reduce the immuno-
genicity, site-directed mutagenesis of amino acid residues
to diminish immunogenicity without reduction of enzym-
atic activity, consequent use of L-asparaginases with dif-
ferent immunogenic properties. The most common way is
a chemical modification of the protein, for instance, con-
jugation with polyethylene glycol (PEG). It was shown that
pegylation significantly increases the half-life (T1/2) of EcA
in human serum, from 1.24 ± 0.17 to 5.73 ± 3.24 days [3,
4]. However, if the patient is allergic to native EcA, the T1/
2 of pegylated EcA also decreases, which is due to identical
antigenic epitopes [5]. Besides pegylation, several ap-
proaches have demonstrated the ability to decrease im-
munogenicity, namely encapsulation into liposomes 158–
180 nm [6], immobilization into a biocompatible poly-
ethylene glycol-albumin hydrogel [7], formulation of L-
asparaginase load poly(lactide-to-glycolide) nanoparticles
[8], chemical modification by N, O-carboxymethyl chito-
san [9], etc. For example, encapsulation of palmitoyl-
asparaginase into liposomes increases the T1/2 of native
EcA for at least eight times [10]. Conjugation with low-
immunogenic and non-toxic proteins, for instance silk fi-
broin, or encapsulation into red blood cells in vitro could
be used for hiding the epitopes of L-asparaginases and,
therefore, increase of T1/2 [11–14].
Epitope mapping and subsequent production of antigen-
ically modified enzymes can be considered as the second
efficient method to minimize immunogenicity. It has been
proved that the major antigenic epitope of Erwinia
chrysanthemi (ErA) is 282GIVPPDEELP287, and replace-
ment Pro285 with Thr285 has led to 8-fold decrease of the
immunogenicity of the native enzyme [15]. However, the
immune response for large proteins is usually complex,
and antibodies produced are usually polyclonal, hence the
replacement of one amino acid can’t prevent the forma-
tion of antibodies against modified protein in hypersensi-
tive mice previously treated with native one.
The third method that has been used is the consecu-
tive administration of L-asparaginases with different
antigenic properties. It is known that anti-EcA anti-
bodies do not interfere with the ErA pharmacokinetics,
which is the reason why ErA can be effectively used in
patients previously treated with EcA [16–18]. Adminis-
tration of new L-asparaginases, that do not have cross-
reactivity with EcA and ErA, could be an effective ap-
proach for treatment of hypersensitive patients who have
received multiple doses of EcA and/or ErA. It has been
proven that Helicobacter pylori L-asparaginase has dif-
ferent immunogenic properties from EcA in mice [19].
During the last 7 years we’ve obtained and evaluated the
enzymatic and anticancer properties of a few recombinant
L-asparaginases from different origin, namely Wollinella
succinogenes type II (WsA), Yersinia pseudotuberculosis
type II (YpA), Erwinia carotovora type II (EwA), and
Rhodospirillum rubrum type I [20–22].
The aims of this study were the evaluation of the im-
munogenicity in mice and cross-reactivity between these
L-asparaginases and EcA, and elucidation of its structural
basis based on analysis of three-dimensional structures.
Methods
Bioinformatics
Structure-based multiple sequence alignment of EcA,
WsA, EwA, YpA and RrA was constructed using PRO-
MALS3D [23]. Three-dimensional structure of the WsA,
EwA, YpA and RrA proteins were modeled by I-TASSER
[24]. Epitopes experimentally verified for ErA [15] were
projected on the structure-based alignment using
sequence-to-profile alignment method implemented in
Clustal Omega [25]. Bioinformatics prediction of epitopes
were made by Discotope [26], ElliPro [27] and EPSVR
[28]. UCSF Chimera [29] was used for visualization of
the 3D structure of enzymes. Solvent accessibility of the
tetramer was calculated by DSSP [30].
Reagents
L-asparagine (Reanal, Hungary); Na2HPO4, NaH2PO4,
KCl (Serva, Germany); NaCl (Merck, Germany); Tween-
20, NaHCO3, Na2CO3 (Sigma-Aldrich, USA). We used
standard buffers: PBS, pH 7.4; carbonate-bicarbonate
buffer 0.1 M, pH 9.5, citrate-phosphate buffer, 0.1 M,
pH 5.0, PBS-Tween 0.05 %.
Enzymes (antigens)
We used the commercially available lyophilized EcA prep-
aration (Medak, Germany, 10 000 IU per vial); lyophilized
recombinant EwA, that is similar to ErA (Additional file 1:
Figure S1, http://purl.org/phylo/treebase/phylows/study/
TB2:S18796) [22], lyophilized recombinant YpA [20],
lyophilized recombinant RrA, obtained from IBMC
RAMS [21], and lyophilized recombinant WsA, ob-
tained from GosNIIgenetika.
Animals
Female C57Bl6j 8–12 weeks old mice were used for the
in vivo studies. Mice were kept in animal facility of N.N.
Blokhin Cancer Research Center of RAMS. All animal
studies were carried out using procedures in compliance
with EU (European Convention for the Protection of
Animals Kept for Experimental and other Scientific
Purposes, Strasbourg, 1985; 86/609/EEC and 2010/63/
EU) directives on the protection of animals used for
scientific purposes and according to institutional policy
on the care and use of laboratory animals. The animal
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studies were approved by the local ethics committee of
I.I. Mechnikov Institute of vaccine and sera, the decision
from 26/01/2015.
Immunogenicity studies
To evaluate the IgM immune response, groups of mice
(five mice per group) received one i.v. injection of
500 μg of each preparation. To evaluate the IgG immune
response 300 μg of each L-asparaginase were adminis-
tered i.v. 3 times, at 2-week intervals. 0.9 % sodium
chloride solution was injected in a separate groups of
animals as controls (five mice per group). Blood samples
were collected 7 days after the last immunization.
Plasma samples for ELISA assay were obtained by cen-
trifugation at 400 g at 4 °C for 10 min and stored at
−80 °C until analysis. Then the samples were incubated
for 10 min, centrifuged at 10,000 rpm (Eppendorf 1500)
at 24 °C and were used immediately for experiments.
Serum Ab responses were determined using an ELISA
kit (Maxisorb, Nunc). Briefly, standards, controls and pre-
diluted samples of 100 μl of different L-asparaginases in
carbonate-bicarbonate buffer, 5 μg/ml, were added into
the wells of a 96-well plates and incubated at + 4 °C for
12 h. The plate was washed several times for 2 min with
300 μl phosphate buffer saline containing 0.05 % Tween
20 (PBS-Tween).
Serial dilutions (1:50 to 1:256,000) of mouse plasma
were prepared. Following a 1 h incubation at 37 °C, the
wells were washed as described above and the residual ac-
tivity was measured. Serum Ab binding was detected
using polyclonal secondary goat Ab to mouse total IgG or
IgM. We used pre-diluted GoatAnti mouse IgG or Goa-
tAnti mouse IgM, HU ADS biotin conjugate (Invitrogen,
Cat# M30115) 1:10000, 100 μl in each well, and streptavi-
dine conjugate of horseradish peroxidase STREPTAVIDIN
HRP (AbD Serotec) 1:10000, according to manufacturer’s
instructions. After suitable washing, standard buffer for
ELISA was added and the plate was incubated for 15 min
at room temperature. The reaction was stopped by adding
50 μm of 1.8 M H2SO4 before measuring the optical dens-
ity at 450 nm using a plate reader Multiscan FC.
For IgG response the serum was considered negative
(−) if geometric mean of the titers (GMT) was <50, posi-
tive: 51–600 (+), 601–30,000 (++), and >30,000 (+++).
For IgM response the serum was considered negative (−)
if GMT was <50, positive: 51–125 (+), 126–300 (++),
and >300 (+++).
Statistical analysis
Geometric mean of the titers (GMTs) and the GMT ra-
tios with corresponding 95 % confidence intervals (CIs)
were calculated by taking the antilog of the mean of the
logе-transformed data (assuming that logе-transform-
ation of the titers follows a normal distribution).
To compare immunogenicity of different antigens we
used GMT of each antigen reacting with the serum sam-
ple from mice immunized with the same antigen. For in-
stance, EcA + anti-EcA vs YpA + anti-YpA. To prove
statistical validity of cross-immunogenicity between
groups we used GMT of each antigen reacting with the
serum sample from mice immunized with the different
antigen vs antigen reacting with the serum sample from
control mice (no immunization).
SPSS 21 software was used for statistical analysis.
One-way ANOVA was used to compare immunogenicity
of antigens. Post hoc Dunnett’s T3 test was performed to
assess differences between the individual groups. Calcu-
lations began with the logarithmic transformation of the




The anti-L-asparaginase IgG were developed following
repeated i.v. administration of enzymes. The most im-
munogenic L-asparaginase was found to be YpA
(Table 1). GMTs of different enzymes varied from 275
(95 % CI 80–949) for EcA to 111431 (95 % CI 75831–
163743) for YpA, with 795 (95 % CI: 10–63293) for
EwA, 18379 (95 % CI: 7159–47182) for WsA and 26909
(95 % CI: 7159–47182) for RrA. The difference between
YpA and all other enzymes was statistically significant
(p < 0.001), suggesting YpA was most immunogenic
compared to EcA, EwA, WsA and RrA in murine
model. WsA, RrA and EwA showed similar immuno-
genicity without statistically significant differences.
Thus, studied L-asparaginases might be placed in the
following order based on the immunogenicity: YpA >
RrA, WsA ≥ EwA > EcA (Fig. 1, Table 2).
IgM immune response
The inhibitory titers per mice were the following: 1:400–
1:1600 for YpA, 1:400–1:800 for RrA and 1:200–1:800 for
EcA, EwA and WsA, GMTs are 400 (95 % CI: 218–735)
for EcA, 528 (95 % CI: 244–1140) for WsA, 210 (95 % CI:
5–9036) for YpA, 159 (95 % CI: 5–5520) for RrA, 459
(95 % CI: 224–944) for EwA (Table 3). All enzymes
showed similar immunogenicity without statistically
significant differences.
Cross-reactivity of L-asparaginases
As it is shown in Table 4, sera from mice injected with
EcA 3 times showed no statistically significant cross-
reactions with all other enzymes. The immunization with
WsA led to formation of antibodies against EcA (p = 0.029
compared with naïve control), however, the GMT was 353
times (WsA/EcA × 353) lower than for GMT for WsA +
anti-WsA reaction. Sera obtained from mice treated with
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YpA were positive to all other enzymes if compared with
naïve control with the following ratio ratings: YpA/EcA ×
169, YpA/WsA× 308, YpA/RrA × 671 and YpA/EwA×
2228, displaying EcA as an antigenically closest equivalent
to YpA. After multiple administration of RrA the statisti-
cally significant immune response was detected against
YpA: RrA/YpA × 215. For EwA: EwA/EcA× 5, suggesting
that the strongest immune response among studied en-
zymes can be obtained in mice treated with EcA after EwA.
Evaluation of IgM immune response confirmed the
cross-reactivity between EcA and YpA. The most signifi-
cant cross-reactions were: GMT for EcA: EcA/YpA × 4.6;
GMT for WsA: WsA/EwA × 4.6 and WsA/RrA × 4.6;
GMT for YpA: YpA/WsA × 1.6 and YpA/EcA × 2.8;
GMT for RrA: RrA/YpA × 1.5; GMT for EwA: EwA/
YpA × 4.6. All cross-reactions were statistically signifi-
cant against naïve control (p <0.001). However, the bio-
medical implications of these findings can be compromised
due to very low intrinsic IgM-response of all studied pro-
teins (see section “IgM immune response”) and presumable
non-specific reactions of serum in sensitized animals.
Prediction and structural comparative analysis of epitopes
To elucidate a nature of the L-asparaginase immunogen-
icity and to optimize the development of the bacterial L-
asparaginases with reduced immunogenicity for therapeutic
use, we performed a comparative structural and sequence
analysis of putative epitopes. The presumable epitope re-
gions were obtained using bioinformatics prediction and
sequence-based projection of the experimental data existing
for homologous proteins. First, we mapped experimentally
verified epitopes known for ErA, which is the close homo-
log of the five considered enzymes, into 3D structure of en-
zymes using multiple sequence alignment. A solved three-
dimensional structure of the EcA enzyme was taken from
PDB, whereas 3D structures of other four enzymes were
modeled using state-of-the-art software (see Methods)
implementing homology modeling approach. Second, we
used three bioinformatics methods to obtain consistent
protein epitope predictions, which support and comple-
ment the experimental epitope projection results. The re-
sults of these methods consistently indicated nine regions
of the enzyme as putative epitopes (Fig. 2).
Five out of these nine regions represent active site loops
(Fig. 3), three of which are located in the N-terminal do-
main and two in the C-terminal domain. Four other puta-
tive epitope regions are two C-terminal domain helices, a
region consisting of two parallel beta-strands involved in
inter-subunit contacts and inter-domain linker. Since the
bioinformatics methods of epitope prediction were applied
for monomeric protein, we additionally investigated acces-
sibility to solvent all of the predicted regions as a part of
tetrameric structure to check whether these regions are
accessible to antibodies (Fig. 2). Among the projected




EcA WsA YpA RrA EwA
Control – – – – –
EcA + – – – –
WsA + ++ – – –
YpA ++ + +++ + –
RrA – – + ++ –
EwA + – – – ++
Fig. 1 GMTs for serum anti-L-asparaginases-specific neutralizing anti-
bodies, IgG response
Table 2 Pair-wise comparison of immunogenicity of L-




WsA YpA RrA EwA
EcA 0.001 <0.001 0.001 0.989
WsA 0.026 0.954 0.440
YpA 0.005 0.169
RrA 0.352




EcA WsA YpA RrA EwA
Control – – – – –
EcA +++ + + – +
WsA + +++ + + +
YpA + ++ ++ – +
RrA – + + ++ +
EwA – + + + +++
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experimentally verified epitopes, two most confident ones
are the regions of the active site, of which the first is lo-
cated in the longest and highly protruding N-terminal
loop (active site loop#1 in the Fig. 3) and the second is lo-
cated in the C-terminal helix near the loop participating
in the active site contacts with the substrate [31].
We performed structural comparison of the putative
epitope regions for all five studied L-asparaginases.
Superimposition of the N-terminal domain parts of the
active site for five considered proteins did not show any
substantial structural differences for the three active site
loops (Fig. 4c). The only detectable difference worth
mentioning is the shorter length of the RrA loops. Pre-
dicted epitopes located in loops and helices of the C-
terminal part of the active site of four enzymes except
RrA (due to lack of C-terminal domain) are also





GMT, 95 % CI
EcA WsA YpA RrA EwA
EcA GMT 2.2 (0.2–19.2) 2.6 (0.2–38.4) 6.9 (0.3–184.0) 6.6 (0.2–176.2)
p 0.935 0.875 0.413 0.432
WsA GMT 52.3 (2.8–979.2) 6.9 (0.3–184.0) 5.7 (0.3–115.3) 10.5 (0.7–149.6)
p 0.029 0.437 0.521 0.277
YpA GMT 659.8 (178.9–2433.6) 362.4 (77.0–1705.7) 165.7 (3.3–8296.3) 50.0 (50.0–50.0)
p <0.001 <0.001 <0.001 0.003
RrA GMT 4.7 (0.0–663.9) No response 125.0 (125.0–125.0) 7.1 (0.2–257.2)
p 0.475 0.002 0.284
EwA GMT 148.7 (85.6–258.0) No response 7.1 (0.2–257.2) 8.9 (0.2–514.8)
p <0.001 0.201 0.135
Fig. 2 Structure-based multiple sequence alignment of five studied L-asparaginases. Four lines below the alignment show putative epitope
region predicted by EPSVR, Discotope, and ElliPro methods, respectively, as well as the experimentally known epitopes projected from the
Erwinia chrysanthemi L-asparaginase. Lines above the alignment represent the secondary structure and the estimation of solvent accessibility
of EcA tetramer
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structurally very similar to each other (Fig. 4a), except
for a much shorter active site loop (active site loop#5 in
the Fig. 3) of the EwA. Two antiparallel beta-strands of
the multi-subunit interface show almost complete simi-
larity in structural sense (Fig. 4d). Some structural differ-
ences were detectable among the domain linkers
(Fig. 4b). Thus, the YpA enzyme has the shortest domain
linker in comparison to other three enzymes, EcA and
WsA enzymes have the longest ones, and EwA linker
has an intermediate length.
We also analyzed amino acid content of the presumable
epitope regions in order to compare enrichment in amino
acids, which are known for increased immunogenicity —
tyrosine, tryptophane and charged aminoacids [32]. The
N-terminal active site loops of the four type II asparagi-
nases have sufficiently similar amino acid content,
whereas the RrA has a larger number of charged amino
acids. Putative C-domain epitope regions are sufficiently
conserved among studied L-asparaginases, although the
EwA has a larger number of charged amino acids. A
multi-subunit interface represented by two short anti-
parallel strands contains three tyrosines and two
charged amino acids in case of YpA and WsA, two
tyrosines and two charged amino acids in EcA and one
tyrosine and one charged amino acid in EwA. Amino
acid content of the inter-domain linker region does not
show any substantial differences among the considered
enzymes.
Discussion
We performed a comparative analysis of structure and
sequence of the bacterial L-asparaginase epitope regions,
which were predicted by bioinformatics methods and
projected from the experimentally known epitope re-
gions of the homologous proteins. Particularly, we ana-
lyzed whether the presumable epitope regions differ
among considered enzymes and whether these differ-
ences are associated with known structure and sequence
Fig. 3 Three-dimensional structure of the EcA protein with a color mapping representing the example of the epitope prediction obtained by
EPSRV method (blue – low probability, red – high probability). Following key structural elements of the enzyme are designated in the figure:
three N-terminal active site loops, two C-terminal active site loops, multi-subunit interface regions and inter-domain linker. Inset: Tetrameric struc-
ture of Escherichia coli L-asparaginase EcA
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elements that influence immunogenicity. Analysis of the
secondary structure showed that the secondary structure is
highly conserved among considered enzymes and most of
the presumable epitopes regions are located in loops that is
in accordance with structural studies [32]. Protrusion and
solvent accessibility of the considered loops – two proper-
ties that are known for affecting immunogenicity – are suf-
ficiently similar among the enzymes, except for N-terminal
active site loops of the RrA, which are much shorter than
the same loops of other enzymes. We also found a moder-
ate differences among enzymes in a length of the inter-
domain linker region.
Analysis of differences in amino acids associated with
increased immunogenicity – tyrosine, tryptophane and
charged amino acids – showed more differences than the
structural analysis. Among these differences the most cor-
related with experimental data is the difference among en-
zymes in enrichment of tyrosines and charged amino
acids in the multi-subunit interface region. However,
structural properties of this region – a presence of two
beta-strands and a moderate solvent accessibility – is not
typical for epitopes. Apart from the predicted epitopes the
N- and C-terminal ends of protein could be also consid-
ered as putative epitopes when they are long enough to
possess enough protrusion and flexibility – two character-
istic epitope properties. We speculate that a long N-
terminus of YpA enzyme (see sequence alignment in
Fig. 2), which is also enriched at the beginning with
charged aminoacids and tyrosine (KYIK), could be a rea-
son of higher immunogenicity of YpA in comparison with
other considered enzymes. Overall, although the recog-
nized structural and sequence differences in putative epi-
tope regions among five considered L-asparaginases do
not fully explain experimental observation of the im-
munogenicity of the enzymes, the performed analysis set
the foundation for further research in this direction when
more data are available.
There are two approaches to describe the cross-
reactivity of antibodies: either L-asparaginase could be
considered as an antigen for immunization or the en-
zyme is defined as a target for antibodies. The obtained
data showed that after single and threefold administra-
tion all investigated L-asparaginases displayed moderate
immunogenicity with low cross-reactivity. The anti-
bodies produced in mice after EcA administration have
the worst capacity for development of cross-reactivity
with other enzymes. This phenomenon could be explained
mainly by low immunogenicity of EcA, confirming the
current position of EcA as a first-line L-asparaginase for
acute lymphoblastic leukemia treatment. Any other en-
zyme, preferably WsA, YpA or RrA could be used as a
second-line treatment without a risk of significant alter-
ation of pharmacokinetics due to antibodies formation.
However, EcA could be a target for antibodies produced in
Fig. 4 Superimposition of the predicted epitopes of EcA (red), EwA (yellow), WsA (green), YpA (blue) L-asparaginases including C-terminal active
site loops (a), inter-domain linker (b), N-terminal active site loops (c), and multi-subunit interface regions (d)
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mice previously immunized with any other L-asparaginase.
It could be explained both by higher immunogenicity of
these enzymes and presence of similar epitopes in EcA and
other enzymes, that was shown by analyses of three-
dimensional structures. The affinity of cross-binding with
EcA and other L-asparaginases vary directly as the average
immunogenicity of each enzyme: YpA showed the highest
cross-reactivity, that can be explained by more than 74 %
homology of the sequences of EcA and YpA. The differ-
ences in cross-reactivity of each L-asparaginase evaluated
by these two different approaches could be explained by
different location of antigenic epitopes (internal or exter-
nal epitopes).
The clinical relevance of our findings can be evaluated
after comprehensive preclinical investigation of safety
and efficacy of obtained enzymes and consequent clin-
ical trials. The clinical pathway requires comparative tri-
als of efficacy and safety of new L-asparaginases in
patients with acute lymphoblastic leukemia, previously
treated with EcA.
Conclusions
The performed study showed different immunogenic
properties of L-asparaginases and confirmed the possi-
bility of replacement of EcA with L-asparaginase from
different origin. YpA was most immunogenic enzyme
compared to EcA, EwA, WsA and RrA in murine
model. Based on these data, the preferable enzyme for
the second line treatment is WsA, RrA or EwA. Fur-
ther investigations of the epitopes and immunogenicity
of novel L-asparaginases are needed to assume their
therapeutic applications or create the mutated proteins
with minimized immunogenicity in order to increase
the efficacy of leukemia treatment.
Additional file
Additional file 1: Figure S1. Phylogenetic tree of the WaA, YpA, EwA,
RrA, EcA, ErA L-asparaginases. ErA has a minimal evolutionary distance to
the EwA L-asparaginase. (PNG 20 kb)
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